drugset
Drugs / Sacubitril / Valsartan
last change Dec 2024 re-read 9 days ago

Sacubitril / Valsartan

also known as Entresto

Other / unclassified

Developed for
Chagas cardiomyopathy

Trials 0

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Comparator or background therapy1 trial
Phase 3 NCT04853758 Comparator May 2021 → Dec 2024 Chagas cardiomyopathy University of Sao Paulo General Hospital Unknown No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2023-07-07 Novartis Pharmaceuticals Novartis will appeal to U.S. Court of Appeals to uphold validity of Entresto® combination patent; maintains 2023 guidance and mid-term outlook novartis.com ↗

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Sacubitril / Valsartan ClinicalTrials.gov intervention name — accepted as the source's own label NCT04853758 ↗
Known as Entresto “Sacubitril / Valsartan Oral Tablet [Entresto]” NCT04853758 ↗
Action Inhibit “This new molecule acts by blocking AII AT1 (angiotensin type 1) receptors” NCT04853758 ↗
Modality Other / unclassified “new drug class (ARNI: angiotensin receptor-neprilisin inhibitor)” NCT04853758 ↗
Route Oral “Sacubitril / Valsartan Oral Tablet [Entresto]” NCT04853758 ↗